Barrett's Esophagus With Low-Grade Dysplasia: Ablation or Continued Surveillance
Confirmed, pathologist-reviewed low-grade dysplasia in Barrett's esophagus is a real fork in real practice — endoscopic ablation lowers progression risk in trial data, but continued surveillance on optimized medical therapy remains a legitimate, guideline-recognized alternative, and the choice here turns on how much weight to give one pathologist's read.
Susan K., 59, has spent every summer for the past two decades at the same lake house her parents left her, now the one who organizes which grandchildren come which week — a rhythm she's protective of and doesn't want a procedure schedule interfering with more than it has to. She's had Barrett's esophagus for nine years, stable on non-dysplastic surveillance biopsies until this year, when her most recent endoscopy showed a focal area read as low-grade dysplasia by the community pathologist. Per standard practice for a first LGD read, the slides were sent for confirmation to a second, GI-specialized pathologist, who agreed with the diagnosis — a genuine, two-pathologist-confirmed LGD finding, not a single read carrying the usual real interobserver disagreement this diagnosis is known for.
The randomized trial behind current practice is SURF (Phoa and colleagues, JAMA 2014), which stopped early after progression to high-grade dysplasia or cancer occurred in 1.5% of ablated patients against 26.5% under surveillance — a 25-point absolute difference, and the reason most guidelines now favor ablation for confirmed LGD. But surveillance with optimized medical therapy — high-dose PPI, with aspirin as a reasonable adjunct per the same chemoprevention data discussed in Barrett's patients generally — remains a guideline-recognized alternative, not a rejected one, particularly for a patient weighing a summer she's built her family's whole rhythm around against a procedure with its own real, if modest, risk of stricture and other complications. Her two-pathologist confirmation is what makes those numbers hers. Interobserver agreement on a first LGD read runs low — Curvers and colleagues found a large share of community-read LGD downgraded to no dysplasia on expert review — which is precisely why guidelines call for that second read before treating LGD as confirmed, and precisely why Susan's diagnosis, having cleared that bar, carries more weight than a single-pathologist LGD read typically would. Susan was also told plainly that "legitimate alternative" doesn't mean equivalent in every respect — ablation's trial-level risk reduction is real, and choosing surveillance means accepting a higher, if still modest, residual progression risk in exchange for avoiding a procedure now, a tradeoff the team wanted stated in those specific terms rather than softened.
A confirmed diagnosis, two legitimate paths forward
I'd recommend ablation. Current guidelines favor it for confirmed LGD, and randomized trial data shows real reduction in progression to high-grade dysplasia or cancer compared to surveillance alone. What makes this case cleaner than most LGD discussions is that her diagnosis was confirmed by two independent pathologists — we don't have the usual interobserver-disagreement question hanging over whether this is even real dysplasia.
I agree the diagnosis is solid, and I'm not arguing against ablation as a reasonable choice. What I want on the table is that continued surveillance with optimized medical therapy is still a guideline-recognized alternative, not a rejected one — this isn't a settled-versus-outdated comparison, it's two legitimate options with different risk-benefit profiles.
Ablation's own complication profile, including stricture, is real and worth naming with the same weight we're giving its benefit.
Susan has organized her family's whole summer rhythm around that lake house for twenty years, and that's not a trivial preference to weigh against a procedure with real, if modest, complication risk of its own. I don't think either of you is wrong on the medicine — I think this is exactly the kind of decision where the guideline correctly leaves room for her to choose, once she genuinely understands both the trial data behind ablation and the fact that surveillance remains a legitimate path, not a lesser one.
Agreed: PPI increased to 40mg daily and aspirin started now, regardless of which path she ultimately chose. After a full discussion of both options' real trial data and guideline status, Susan chose ablation over indefinite surveillance, but asked to schedule it for the fall rather than sooner.
Not fully agreed: the gastroenterologist would have preferred scheduling it sooner given the confirmed diagnosis, but accepted the deferral once it was clear the modest absolute risk over a few additional months was a trade Susan was making with full information, not an avoidance of the decision itself.